Mipomersen sodium
Modify Date: 2025-08-25 17:37:10
Mipomersen sodium structure
|
Common Name | Mipomersen sodium | ||
|---|---|---|---|---|
| CAS Number | 629167-92-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C230H305N67Na19O122P19S19 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Mipomersen sodiumMipomersen (sodium) is a second-generation 20-base phosphorothioate ASO targeted to human apoB-100[1][2]. |
| Name | MipoMersen sodiuM |
|---|---|
| Synonym | More Synonyms |
| Description | Mipomersen (sodium) is a second-generation 20-base phosphorothioate ASO targeted to human apoB-100[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Mipomersen predominantly distributes to the liver and decreases the production of apoB-100, the primary structural protein of the atherogenic lipoproteins including low density lipoprotein (LDL), thereby reducing plasma LDL-cholesterol and apoB-100 concentrations[2]. Apolipoprotein (apo) B, a large amphipathic protein, plays a fundamental role in human lipoprotein metabolism. ApoB-100 is also a ligand for LDL receptor-mediated endocytosis of LDL by cells[2]. |
| References |
[1]. Philip Hair, et al. Mipomersen sodium: first global approval. Drugs. 2013 Apr;73(5):487-93. |
| Molecular Formula | C230H305N67Na19O122P19S19 |
|---|
| Kynamro |
| mipomersen |